Abionyx Pharma SA (ABNX) - Total Assets
Based on the latest financial reports, Abionyx Pharma SA (ABNX) holds total assets worth €12.98 Million EUR (≈ $15.17 Million USD) as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Abionyx Pharma SA - Total Assets Trend (2013–2024)
This chart illustrates how Abionyx Pharma SA's total assets have evolved over time, based on quarterly financial data. Also see Abionyx Pharma SA market capitalisation for the company's overall valuation and market capitalisation.
Abionyx Pharma SA - Asset Composition Analysis
Current Asset Composition (December 2024)
Abionyx Pharma SA's total assets of €12.98 Million consist of 43.6% current assets and 56.4% non-current assets. Review ABNX total debt and obligations to assess the company's total debt and financial obligations.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 24.1% |
| Accounts Receivable | €2.29 Million | 17.1% |
| Inventory | €211.00K | 1.6% |
| Property, Plant & Equipment | €1.98 Million | 14.8% |
| Intangible Assets | €77.00K | 0.6% |
| Goodwill | €5.38 Million | 40.0% |
Asset Composition Trend (2013–2024)
This chart illustrates how Abionyx Pharma SA's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See ABNX stock price for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Abionyx Pharma SA's current assets represent 43.6% of total assets in 2024, a decrease from 98.8% in 2013.
- Cash Position: Cash and equivalents constituted 24.1% of total assets in 2024, down from 80.0% in 2013.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 39.0% of total assets, an increase from 0.0% in 2013.
- Asset Diversification: The largest asset category is goodwill at 40.0% of total assets.
Abionyx Pharma SA Competitors by Total Assets
Key competitors of Abionyx Pharma SA based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Tubize-Fin
BR:TUB
|
Belgium | €1.99 Billion |
|
Dianthus Therapeutics Inc.
NASDAQ:DNTH
|
USA | $1.21 Billion |
|
Tango Therapeutics Inc
NASDAQ:TNGX
|
USA | $1.07 Billion |
|
Damora Therapeutics, Inc.
NASDAQ:DMRA
|
USA | $543.64 Million |
|
Apnimed, Inc. Common Stock
NASDAQ:APMD
|
USA | $342.63 Million |
|
Wecome Pharmaceutical Co Ltd
SHE:300878
|
China | CN¥1.49 Billion |
|
Tectonic Therapeutic, Inc.
NASDAQ:TECX
|
USA | $246.58 Million |
|
Relmada Therapeutics Inc
NASDAQ:RLMD
|
USA | $235.36 Million |
Abionyx Pharma SA - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.40 | 2.28 | 2.66 |
| Quick Ratio | 1.35 | 2.22 | 2.72 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €1.57 Million | €4.24 Million | €5.67 Million |
Abionyx Pharma SA - Advanced Valuation Insights
This section examines the relationship between Abionyx Pharma SA's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 22.00 |
| Latest Market Cap to Assets Ratio | 5.60 |
| Asset Growth Rate (YoY) | -9.3% |
| Total Assets | €13.45 Million |
| Market Capitalization | $75.31 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Abionyx Pharma SA's assets at a significant premium (5.60x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Abionyx Pharma SA's assets decreased by 9.3% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Abionyx Pharma SA (2013–2024)
The table below shows the annual total assets of Abionyx Pharma SA from 2013 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | €13.45 Million ≈ $15.72 Million |
-9.33% |
| 2023-12-31 | €14.83 Million ≈ $17.34 Million |
-6.25% |
| 2022-12-31 | €15.82 Million ≈ $18.50 Million |
-27.52% |
| 2021-12-31 | €21.83 Million ≈ $25.52 Million |
+112.21% |
| 2020-12-31 | €10.29 Million ≈ $12.03 Million |
+0.38% |
| 2019-12-31 | €10.25 Million ≈ $11.98 Million |
-21.97% |
| 2018-12-31 | €13.13 Million ≈ $15.36 Million |
-28.21% |
| 2017-12-31 | €18.30 Million ≈ $21.39 Million |
-37.05% |
| 2016-12-31 | €29.07 Million ≈ $33.98 Million |
-36.96% |
| 2015-12-31 | €46.11 Million ≈ $53.90 Million |
+325.46% |
| 2014-12-31 | €10.84 Million ≈ $12.67 Million |
-22.18% |
| 2013-12-31 | €13.93 Million ≈ $16.28 Million |
-- |
About Abionyx Pharma SA
ABIONYX Pharma SA, a biotech company, discovers and develops therapies for the treatment of renal and ophthalmological diseases. It develops CER-001, a negatively-charged lipoprotein particle that contains human recombinant apoA-I, the natural high-density lipoprotein (HDL) protein, and sphingomyelin and dipalmitoylphosphatidylglycerol natural phospholipids designed to mimic the structural and fu… Read more